Huge reversal potential in this stock right nowHammer right at major structure and 618. Beautiful long here for a reversal and continued upside. Notice, the intraday neckline is the 618 of the daily. And there's more! There is also a trend line that seems to be important.. A LOT of confluence. Longby LanmarUpdated 7
IOVA will rage higher?Biotech stocks have shown relentless strength lately, including $IOVA. I wouldn't be surprised to see that IOVA rejects this move downward soon and soars back up (i.e., reverts to trend). That moving average keeps cranking higher.Longby dotpem225
$IOVAHammer on daily. Breakout at 8 EMA could push it towards mid to high 30s.Longby IncredibleTrade4
SPCE AMRN APT IOVA STOCK CHARTS!!VIRGIN GALACTIC MRNA APT IOVA STOCK CHARTS!!!Long06:18by BlockTraderJoe6
#IOVA #IOVA very orderly pull back trying rest 21.41 again ..we shall see , but shorts having good day imo or week already Longby mralexsellUpdated 3
$IOVA LOOKS SET FOR CONTINUATION TODAY, BIG GAINS*****CONTINUATION LOOKS ON THE CARDS TODAY, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOD VOLUME . CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING. ***********NEWS FLOW********* The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that has progressed on or after chemotherapy. Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.Longby DEXWireNews5
$IOVA SETTING UP FOR STRONG MOVE TOMORROW, FDA REVIEW******CONTINUATION LOOKS ON THE CARDS TOMORROW, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOV VOLUME. CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING. ***********NEWS FLOW********* The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that has progressed on or after chemotherapy. Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.Longby RedHotStocks4
$IOVA Positive Test Results gives surge in priceShares of Iovance Biotherapeutics, a clinical-stage biotechnology company, are on the move after a clinical program update. Investors who are pleased to see the company's oncology candidates getting closer to the finish line pushed the stock 20.4% higher on Wednesday.Longby DEXWireNews4
kickback on 5 year base3k June $15 calls traded vs 1,233 OI. Two conf coming $IOVALongby JackyCharts1
Clear uptrend in IOVAI find stocks with this certain structure usually continue to go up. That is, an uptrend where 80%-95% of the days are green and keep their strength when it matters, like the last two weeks. Despite the major move from 8.50 to 18.00 it has held current price and its resilience is shown by staying above the 10dma when it comes to closing prices. Friday was good confirmation that this uptrend isnt over and a 5-6% uptick from here isnt or should be out of the ordinary. The volume is confirmation of strength during these last two days. Fridays rally shows a lot of strength coming back from a -7% loss and is not to be ignored and is one of the primary reasons why this stock is back on my watchlist. This stock is volatile and should be entered with a small position, day traded, and entered at a decent price. Most stocks have a tendency to open slightly down and is why my entry is at 18.70, this of course will change based on how it reacts right out of the opening. Longby I4Updated 1
Price has been bullish but seems to be stable at around $7.79If the market decides to make this stock go uptrend again then a next key level might be $8.11. If not, or for speculators expecting a bearish trend, another key level might be $7.60. Manage your risk exposure correctly :)by investdata113
IOVA - good long term holdIOVA has FDA fast track approval for new cancer immune therapy drug Longby rollingw1